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Gene transcription lies at the beginning of a
response of a cell to a xenobiotic. Thus, a
transcriptional response can give a prelimi-
nary indication of the biochemical or biologi-
cal mechanism being affected by a xenobiotic,
and gene expression data can provide starting
points in a toxicological examination. The
use of genomics technologies, particularly
gene arrays, as tools for identifying proﬁles of
gene expression associated with particular
compounds and/or toxicities has shown
increasing merit. If a good correlation exists
between gene expression and a toxic mecha-
nism, then the genomic data may provide
supportive evidence for that mechanism
(Chevalier and Roberts 2001; Harries et al.
2001; Lord et al. 2001). Even when the
mechanism is unknown, genomic data can
help identify components (i.e., proteins or
enzymes) of pathways that may be involved
in the biological process under study (Crosby
et al. 2000). Developing databases of expres-
sion proﬁles for a wide variety of toxic com-
pounds and toxic models makes it possible to
create statistical and computational methods
that can indicate the toxic potential of a drug
or chemical from the pattern of gene expres-
sion changes it elicits in in vitro (Brooks and
Pennie 2001; Burczynski et al. 2000; Waring
et al. 2001) or in vivo systems (Hamadeh
et al. 2002). 
Over the past several years there has
been considerable investment by chemical
and pharmaceutical companies, government
agencies, and technology providers in the
application of gene array–based approaches
in chemical and drug development. The
value of genomic approaches to generate
hypotheses is being realized for understand-
ing toxicity and consequently contributing to
an evaluation of drug and chemical safety
both in predictive toxicology and in
mechanism-based risk assessment. 
As the ﬁeld of toxicogenomics emerged
in the late 1990s, it became clear there was
a need to establish a body of available
knowledge to serve as a foundation for
applying the data generated by gene array
methodologies to risk assessment. To this
end, in 1999 the membership of the non-
profit scientific research organization, the
International Life Sciences Institute (ILSI)
Health and Environmental Sciences
Institute (HESI) initiated a collaborative
scientific program—the HESI Committee
on the Application of Genomics to
Mechanism-Based Risk Assessment—to
address issues, challenges, and opportuni-
ties afforded by toxicogenomics (Robinson
et al. 2003). The articles in this mini-
monograph include overviews of the design
and objectives of this experimental pro-
gram (Kramer et al. 2004; Mattes et al.
2004; Newton et al. 2004; Ulrich et al.
2004) as well as a series of technical articles
detailing data generated and analyzed as
part of the HESI genomics research
programs (Amin et al. 2004; Baker et al.
2004; Goodsaid et al. 2004; Mattes 2004;
Rosenzweig et al. 2004; Thompson et al.
2004; Waring et al. 2004). Additional
manuscripts detailing the experimental
findings of the HESI Genotoxicity
Working Group will be published in the
journal Mutation Research in March 2004.
The complete data set is currently being
submitted to ArrayExpress (European
Bioinformatics Institute, Hinxton, UK;
http://www.ebi.ac.uk/arrayexpress) and will
be available for public download by second
quarter 2004. Accession numbers referenc-
ing this data set will be available on the
HESI website (http://hesi.ilsi.org/index.cfm?
pubentityid=120).
Toxicogenomics has progressed con-
siderably during the course of the HESI
Genomics Committee’s research program
(1999–2003). Publications on the subject
evolved from illustrating the theoretical
promise of the technologies (Burchiel
et al. 2001; Fielden and Zacharewski
2001; Nuwaysir et al. 1999; Simmons
and Portier 2002; Smith 2001; Storck
et al. 2002; Tennant 2002; Ulrich and
Friend 2002; Waring and Halbert 2002)
to illustrating the practical use of the
technologies in toxicology (Brooks and
Pennie 2001; Hamadeh et al. 2002; Lord
et al. 2001; Waring et al. 2001). Many of
the initial concerns about the practical
use of toxicogenomics (e.g., oversensitiv-
ity, lack of comparability, availability of
analytical tools) have been addressed,
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The value of genomic approaches in hypothesis generation is being realized as a tool for under-
standing toxicity and consequently contributing to an assessment of drug and chemical safety. In
1999 the membership of the International Life Sciences Institute Health and Environmental
Sciences Institute formed a committee to develop a collaborative scientific program to address
issues, challenges, and opportunities afforded by the emerging field of toxicogenomics. Experts
and advisors from academia and government laboratories participate on the committee, along
with approximately 30 corporate member organizations from the pharmaceutical, agrochemical,
chemical, and consumer products industries. The committee has designed, conducted, and ana-
lyzed numerous toxicogenomic experiments within the broad ﬁelds of hepatotoxicity, nephrotoxi-
city, and genotoxicity. The considerable body of data generated by these programs has been
instrumental in increasing understanding of sources of biological and technical variability in the
alignment of toxicant-induced transcription changes with the accepted mechanism of action of
these agents and the challenges in the consistent analysis and sharing of the voluminous data sets
generated by these approaches. Recognizing the importance of standardized microarray data for-
mats and public repository databases as the mechanism by which microarray data can be com-
pared and interpreted by the scientific community, the committee has partnered with the
European Bioinformatics Institute to develop a database to house the data generated by its collab-
orative research. Key words: genomics, HESI, microarrays, risk assessment, toxicogenomics.
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Genomics and Risk Assessment Mini-Monographalthough several issues still merit
resolution before such data are used fully
in the risk assessment process. 
The HESI Collaborative
Research Program 
The HESI genomics research program was
executed via a multinational team of scien-
tists from academic and government labora-
tories, along with scientists from more than
30 corporate member organizations from
the pharmaceutical, agrochemical, chemical,
and consumer products industries (Table 1).
Participation in the activities of the com-
mittee has afforded the collaborators an
unprecedented opportunity to share
experiences, best-operating practices, and
actual data from a wider cross-section of
commercially available and proprietary plat-
forms, protocols, instrumentation, and
analysis methods than they would have had
access to individually.
Since its inception in 1999, the
committee has conducted and analyzed
toxicogenomics experiments within the
broad ﬁelds of hepatotoxicity, nephrotoxic-
ity, and genotoxicity. These experiments
were designed a) to evaluate responses to
prototypical toxicants to determine if known
mechanisms of toxicity could be associated
with characteristic gene expression proﬁles,
b) to identify technological and biological
sources of variability associated with toxi-
cogenomic experimental protocols, and
c) to ultimately evaluate the utility of this
technology for risk assessment applications. 
The experience highlighted the
challenges inherent in the analysis and shar-
ing of the data sets generated by these
approaches. As reported in this mini-mono-
graph, the experimental program has charac-
terized the biological and technical sources
of variability such as the isolation and label-
ing of mRNA samples, the detection hard-
ware settings, the analysis software threshold
settings, the microarray lot number, and the
differences in gene coverage and probe
annotation across different technical plat-
forms. Nevertheless, in support for toxicoge-
nomics as a valuable tool in assessing
toxicity, the experimental programs have
shown that a) patterns of gene expression
relating to biological pathways are robust
enough to allow insight into mechanisms of
toxicity; b) gene expression data can provide
meaningful information on the physical
location of the toxicity; c) dose-dependent
changes can be observed; and d) concerns
about oversensitivity of the technology may
be unfounded (particularly when compared
with existing in vitro assays for direct- and
indirect-acting genotoxicants). 
Toxicogenomic Data Storage
and Exchange
As part of its mission, the HESI Genomics
Committee also recognized the importance
of standardized microarray data formats and
public repository databases for better com-
parison and interpretation by the broader
scientific community. Because of this, the
committee has partnered with the European
Bioinformatics Institute, to develop a data-
base (Tox-MIAMExpress; www.ebi.ac.uk/
tox-miamexpress/) based on ArrayExpress
database structure (Brazma et al. 2003) and
MIAME (Minimum Information About a
Microarray Experiment) data format
standards (Brazma et al. 2001). The database
will be consistently annotated and integrated
with other relevant information (e.g.,
histopathology, clinical chemistry, gross
observations), employ standard controlled
vocabulary, and be supported by a query and
data analysis interface. This database will
house all the data generated by the HESI
genomics consortium as part of the project
described herein and will be made available
to the public in early 2004. See Mattes et al.
(2004) in this issue for more information.
Toxicogenomics and Risk
Assessment
As the investments made in the application
of genomic technologies mature, there is a
determined effort to bring the full force of
the technology into risk assessment. The
committee’s practical experimental experi-
ence has provided a valuable substrate for
discussions on the technical and logistical
challenges associated with the use of such
data in the regulatory environment. A
workshop with invited academic and regu-
latory participation (representing North
America, Japan, and Europe) was held 5–6
June 2003 in Fairfax, Virginia, to discuss
the findings of the committee’s working
groups (Pettit 2003). The participants were
able to exploit these ﬁndings to form opin-
ions on the implementation and interpreta-
tion of genomic microarray data in the risk
assessment process.
Scientists from government agencies are
encouraging greater input from both the
academic and private sectors in the develop-
ment of data-quality standards and com-
monly accepted analysis methods. The
committee’s work can help answer the
many questions related to the use of toxi-
cogenomic data in regulatory submissions
or other risk evaluations. For example, what
depth of analysis (and in what format) of
gene expression changes is required for sci-
entifically meaningful risk assessment?
Genomic microarrays used in the pharma-
ceutical industry typically are limited to
early-stage predictive assays and are not
used for advanced mechanistic analysis of
compounds in later stages of assessment.
However, it is becoming clear that microar-
ray data results should be placed in an
appropriate biological context (i.e., with
other biological end points) for researchers
to understand mechanisms underlying toxi-
city. The relevance of single gene expression
changes in the absence of pathway-level
gene expression data cannot be assured.
Raw data from publicly referenced
experiments needs to be available via public
toxicogenomic databases [for example,
Tox-MIAMExpress or the Chemical Effects
in Biological Systems (CEBS) being
developed by the National Center for
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Table 1. Organizations participating on the HESI
Committee on the Application of Genomics to
Mechanism-Based Risk Assessment. 
Private-sector participants
Abbott Laboratories
Amgen Inc.
AstraZeneca
Aventis Pharmaceuticals Inc.
Bayer AG
Bayer CropScience AG
Berlex Laboratories
Biogen, Inc.
Boehringer-Ingelheim Pharmaceuticals, Inc.
Bristol-Myers Squibb Co.
E.I. duPont de Nemours & Co.
Eisai Co., Ltd.
Eli Lilly and Co.
GlaxoSmithKline
Hoffmann-La Roche Inc.
Johnson & Johnson Pharmaceutical Research and 
Development, LLC
Meiji Seika Kaisha, Ltd.
Merck & Co., Inc.
Mitsubishi Pharma Corp.
Novartis Pharmaceuticals Corp.
Pﬁzer Inc
The Procter & Gamble Co.
Sankyo Co., Ltd.
Sanoﬁ-Synthélabo Research
Schering AG
Schering-Plough Research Institute
Sumitomo Chemical Co., Ltd.
Syngenta Central Toxicology Laboratory
Tanabe Seiyaku Co., Ltd.
Wyeth Research
Public-sector participants 
Government
European Agency for the Evaluation of Medicinal 
Products
National Institute of Public Health and the 
Environment (RIVM)—Netherlands
U.S. Air Force
U.S. Army Center for Environmental Health 
Research
U.S. Environmental Protection Agency
U.S. Food and Drug Administration
U.S. National Cancer Institute
U.S. National Center for Toxicological Research
U.S. National Center for Toxicogenomics
Academic
McArdle Laboratory for Cancer Research
Medical College of Wisconsin
Michigan State University
The Institute for Genomic Research
University of SurreyToxicogenomics at the National Institute of
Environmental Health Sciences, Research
Triangle Park, NC] to create a knowledge
base that could be used to support genomics
applications in hazard identification.
Furthermore, if successfully implemented
with the appropriate depth of data content,
such databases could serve as robust
resources for advanced queries (e.g., genetic
patterns of toxicity within/across compound
classes, extrapolation of toxicity across
species, ages, or durations of exposure).
Challenges inherent in populating and using
these resources include limitations in the
availability of sequence information about
probes on microarray platforms, use of non-
standard ontologies for toxicology end
points, and relatively few public submis-
sions of genomic data. However, as
reported in this mini-monograph, several
public consortia and organizations (includ-
ing HESI and the NCT) are actively engag-
ing the toxicological community in
addressing these challenges. 
Conclusion
Genomics, and more specifically toxico-
genomics, can no longer be regarded as a
new technology. The technologies are
maturing to the extent that we now have
considerable experience in their use. As evi-
denced in the research conducted by the
HESI Genomics Committee and presented
in this mini-monograph, it is clear that
transcriptional profiles can discriminate
between classes of compounds and some
toxicities. These very preliminary data can
provide users with valuable information for
mechanistic evaluation and may even facili-
tate commercial decisions concerning the
compounds to be developed and how to
develop them. This committee’s collective
experience presented in this mini-mono-
graph also provides awareness of the limits
of sensitivity and reproducibility of the
methods and an understanding of how
transcriptomic data can be interpreted in
the context of the pathology and other bio-
logical data from a toxicology study. As dis-
cussed in this mini-monograph, the
experimental work and ongoing interac-
tions of the participants on the HESI
Genomics Committee represent a unique
opportunity for the integration and distilla-
tion of this collective experience for the
benefit of the regulators and regulated
industries as well as for the toxicology
community as a whole. 
REFERENCES
Amin RP, Vickers AE, Sistare F, Thompson KL,
Roman RJ, Lawton M, et al. 2004. Identiﬁcation of
putative gene-based markers of renal toxicity.
Environ Health Perspect 112:465–479.
Baker VA, Harries HM, Waring JF, Duggan CM,
Ni HA, Jolly RA, et al. 2004. Clofibrate-induced
gene expression changes in rat liver: a cross-
laboratory analysis using membrane cDNA
arrays. Environ Health Perspect 112:428–438.
Brazma A, Hingamp P, Quackenbush J, Sherlock G,
Spellman P, Stoeckert C, et al. 2001. Minimum
Information About a Microarray Experiment
(MIAME)—toward standards for microarray
data. Nat Genet 29:365–371.
Brazma A, Parkinson H, Sarkans U, Shojatalab M,
Vilo J, Abeygunawardena N, et al. 2003.
ArrayExpress—a public repository for microar-
ray gene expression data at the EBI. Nucleic
Acids Res 31:68–71.
Brooks AN, Pennie WD. 2001. Transcript profiling of
the response to environmental hormone mimics.
Comments Toxicol 7:303–315.
Burchiel SW, Knall CM, Davis JW, Paules RS, Boggs
SE, Afshari CA. 2001. Analysis of genetic and epi-
genetic mechanisms of toxicity: potential roles of
toxicogenomics and proteomics in toxicology.
Toxicol Sci 59:193–195.
Burczynski ME, McMillian M, Ciervo J, Li L, Parker JB,
Dunn RT, Hicken S, et al. 2000. Toxicogenomics-
based discrimination of toxic mechanism in HepG2
human hepatoma cells. Toxicol Sci 58:399–415.
Chevalier S, Roberts RA. 2001. Altered mRNA and
protein expression in non-genotoxic hepatocar-
cinogenesis. Comments Toxicol 7:317–331.
Crosby LM, Hyder KS, DeAngelo AB, Kepler TB,
Gaskill B, Benavides GR, et al. 2000. Morphologic
analysis correlates with gene expression
changes in cultured F344 rat mesothelial cells.
Toxicol Appl Pharmacol 169:205–222.
Fielden MR, Zacharewski TR. 2001. Challenges and lim-
itations of gene expression proﬁling in mechanistic
and predictive toxicology. Toxicol Sci 60:6–10.
Goodsaid FM, Smith RJ, Zairov H, Rosenblum IY.
2004. Quantitative PCR deconstruction of dis-
crepancies between results reported by different
hybridization platforms. Environ Health Perspect
112:456–459.
Hamadeh HK, Bushel PR, Jayadev S, Martin K,
DiSorbo O, Sieber S, et al. 2002. Gene expression
analysis reveals chemical-specific profiles.
Toxicol Sci 67:219–231.
Harries HM, Fletcher ST, Duggan CM, Baker VA.
2001. The use of genomics technology to investi-
gate gene expression changes in cultured human
liver cells. Toxicol In Vitro 15:399–405.
Kramer JA, Pettit SD, Amin RP, Bertram TA, Car B,
Cunningham M, et al. 2004. Overview of the appli-
cation of transcription profiling using selected
nephrotoxicants for toxicology assessment.
Environ Health Perspect 112:460–464.
Lord PG, Barne KA, Kramer K, Bacon EJ, Mooney J,
O’Brien S, et al. 2001. cDNA microarrays in inves-
tigative toxicology: a study of differential gene
expression in compound induced cardiac
hypertrophy. Comments Toxicol 7:381–392.
Mattes WB. 2004. Annotation and cross-indexing of
array elements on multiple platforms. Environ
Health Perspect 112:506–510.
Mattes WB, Pettit SD, Sansone S-A, Bushel PR,
Waters MD. 2004. Database development in toxi-
cogenomics: issues and efforts. Environ Health
Perspect 112:495–505.
Newton RK, Aardema M, Aubrecht J. 2004. The utility
of DNA microarrays for characterizing genotoxi-
city. Environ Health Perspect 112:420–422.
Nuwaysir EF, Bittner M, Trent J, Barrett JC, Afshari CA.
1999. Microarrays and toxicology: the advent of
toxicogenomics. Mol Carcinog 24:153–159.
Pettit S. 2003. Toxicogenomics in risk assessment:
assessing the utility, challenges, and next steps.
Workshop sponsored by the ILSI HESI Committee
on the Application of Genomics in Mechanism-
Based Risk Assessment, 5–6 June 2003, Fairfax,
Virginia. Washington, DC:ILSI Press. Available:
http://hesi.ilsi.org/index.cfm?pubentityid=120
[accessed 13 December 2003].
Robinson DE., Pettit SD, Morgan DG. 2003. Use of
genomics in mechanism based risk assessment.
In: Toxicogenomics (Inoue T, Pennie WD, eds).
Tokyo:Springer-Verlag, 194–203.
Rosenzweig BA, Pine PS, Domon OE, Morris SM,
Chen JJ, Sistare FD. 2004. Dye-bias correction in
dual-labeled cDNA microarray gene expression
measurements. Environ Health Perspect
112:480–487.
Simmons PT, Portier CJ. 2002. Toxicogenomics: the
new frontier in risk analysis. Carcinogenesis
23:903–905.
Smith LL. 2001. Key challenges for toxicologists in the
21st century. Trends Pharmacol Sci 22:281–285.
Storck T, von Brevern MC, Behrens CK, Scheel J,
Bach A. 2002. Transcriptomics in predictive toxi-
cology. Curr Opin Drug Discov Devel 5:90–97.
Tennant RW. 2002. The National Center for
Toxicogenomics: using new technologies to
inform mechanistic toxicology. Environ Health
Perspect 110:A8–A10.
Thompson KL, Afshari CA, Amin RP, Bertram TA, Car B,
Cunningham M, et al. 2004. Identiﬁcation of plat-
form-independent gene expression markers of cis-
platin nephrotoxicity. Environ Health Perspect
112:488–494.
Ulrich R, Friend SH. 2002. Toxicogenomics and drug
discovery: will new technologies help us produce
better drugs? Nat Rev Drug Discov 1:84–88.
Ulrich RG, Rockett JC, Gibson GG, Pettit SD. 2004.
Overview of an interlaboratory collaboration on
evaluating the effects of model hepatotoxicants
on hepatic gene expression. Environ Health
Perspect 112:423–427.
Waring JF, Ciurlionis R, Jolly RA, Heindel M, Ulrich
RG. 2001. Microarray analysis of hepatotoxins
in vitro reveals a correlation between gene
expression profiles and mechanisms of toxicity.
Toxicol Lett 120:359–368.
Waring JF, Halbert DN. 2002. The promise of toxi-
cogenomics. Curr Opin Mol Ther 4:229–235.
Waring JF, Ulrich RG, Flint N, Morfit D, Kalkuhl A,
Staedtler F, et al. 2004. Interlaboratory evaluation
of rat hepatic gene expression changes induced
by methapyrilene. Environ Health Perspect
112:439–448.
Mini-Monograph | ILSI HESI Genomics Committee Overview
Environmental Health Perspectives • VOLUME 112 | NUMBER 4 | March 2004 419